MTOR and pancreatic neoplasm: To determine whether combining metformin with targeted mTOR inhibitors may be a logical therapeutic strategy, we treated cell lines with constant-ratio doses of metformin and either the allosteric mTOR inhibitor rapamycin or the catalytic mTOR inhibitor BEZ235, which are known to inhibit pancreatic cancer cell line growth.